1. Mineral excretion in premature infants receiving various diuretic therapies;Atkinson;J. Pediatr.,1988
2. Committee on Extemporaneous Formulations, 1987. ASHP Special Interest Group on Pediatric Pharmacy Practice, Handbook on Extemporaneous Formulations. American Society of Hospital Pharmacists, Bethesda, MD, pp. 45–47.
3. Improvement of solubility and bioavailability of spironolactone by inclusion in β-cyclodextrin;Debruères;Proc. Int. Symp. Control. Release Bioact. Mater.,1985
4. Heykants, J., Meuldermans, W., Van Peer, A., Woestenborghs, R., Lavrijsen, K., Mannens, G., Monbaliu, J., Van Beijsterveldt, L., Van de Velde, V., Jacqmin, P., New aspects on the pharmacokinetic profile and metabolism of Encapsin™ HPB, hydroxypropyl-β-cyclodextrin, after oral and iv administration. 8th International Cyclodextrin Symposium, March 30–April 2, 1996, Budapest, Hungary.
5. Phase-solubility techniques;Higuchi;Adv. Anal. Chem. Instrum.,1965